Betterlife Pharma Inc Financials

BETRF

Source SEC Filings (10-K/10-Q) Data as of Oct 31, 2018 Currency USD FYE January

This page shows Betterlife Pharma Inc (BETRF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BETRF FY2018 2026-06-01

BetterLife Pharma's balance-sheet reset was driven by external financing, while the underlying business still consumed cash.

FY2018's reported net loss of -$121K understated how much the company was actually consuming: operating loss was -$1.0M and operating cash flow was -$396K, which suggests below-operating accounting items narrowed the bottom-line loss without creating cash.

The move from $66K of assets and -$1.7M of equity in FY2017 to $8.8M of assets and $4.6M of equity in FY2018 looks like a capital-structure reset, not an operating turnaround, because the annual data still shows no reported revenue and negative operating cash flow.

From FY2013 through FY2017, liquidity was consistently tight: current ratios stayed below 0.3x and cash never topped $47K, so everyday obligations appear to have depended on creditors or fresh funding. FY2018's $1.5M cash balance gave more breathing room, but it still sat beside $4.2M of liabilities.

Financial Health Signals

Financial health score pending refresh

We are recalculating Betterlife Pharma Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Earnings Quality Low Quality

3.26x

For every $1 of reported earnings, Betterlife Pharma Inc generates $3.26 in operating cash flow (-$396K OCF vs -$121K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-38.3x

Betterlife Pharma Inc earns $-38.3 in operating income for every $1 of interest expense (-$1.0M vs $27K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$121K

Betterlife Pharma Inc reported -$121K in net income in fiscal year 2018.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.5M

YoY+3135.4%

5Y CAGR+236.8%

Betterlife Pharma Inc held $1.5M in cash against $0 in long-term debt as of fiscal year 2018.

Dividends Per Share

N/A

Shares Outstanding

88M

YoY+16.4%

5Y CAGR+19.7%

Betterlife Pharma Inc had 88M shares outstanding in fiscal year 2018. This represents an increase of 16.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-2.6%

Betterlife Pharma Inc's ROE was -2.6% in fiscal year 2018, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$70K

Betterlife Pharma Inc invested $70K in research and development in fiscal year 2018.

Share Buybacks

N/A

Capital Expenditures

N/A

BETRF Income Statement

Metric	FY18	FY17	FY16	FY15	FY13	FY12
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$70K	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$345K	N/A	N/A	$31K+66.9%	$18K	N/A
Operating Income	-$1.0M	N/A	N/A	-$117K	N/A	N/A
Interest Expense	$27K+134.8%	$12K	N/A	$65K+366.6%	-$24K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$121K	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	$-0.11-10.0%	$-0.10	N/A	N/A

Metric	Q3'19	Q2'19	Q1'19	Q4'18	Q3'18	Q2'18	Q1'18	Q4'17
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$65K-25.1%	$87K+1.7%	$85K	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$432K+1.0%	$428K-42.9%	$749K	N/A	$50K-33.3%	$76K+41.9%	$53K	N/A
Operating Income	-$1.4M-19.5%	-$1.2M+18.3%	-$1.4M	N/A	-$185K	N/A	-$286K	N/A
Interest Expense	$135K+39.1%	$97K+43.3%	$68K	N/A	$7K-12.4%	$8K-4.8%	$9K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.4M-138.8%	-$1.4M+12.9%	-$1.6M	N/A	$531K+9652.3%	-$6K+98.3%	-$320K	N/A
EPS (Diluted)	$-0.04	N/A	N/A	N/A	$0.01	N/A	N/A	N/A

BETRF Balance Sheet

Metric	FY18	FY17	FY16	FY15	FY13	FY12
Total Assets	$8.8M+13174.4%	$66K+20.9%	$55K-48.3%	$106K+414.5%	$21K+188.7%	$7K
Current Assets	$1.7M+2513.6%	$64K+22.1%	$52K-49.6%	$103K+431.8%	$19K+254.5%	$5K
Cash & Equivalents	$1.5M+3135.4%	$47K+58.6%	$29K+5.0%	$28K+85.2%	$15K+334.4%	$3K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.2M+134.6%	$1.8M+219.2%	$564K+29.6%	$435K-34.7%	$666K+52.5%	$437K
Current Liabilities	N/A	$1.8M+219.2%	$564K+29.6%	$435K-33.9%	$658K+65.9%	$397K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.6M+365.0%	-$1.7M-240.5%	-$509K-54.7%	-$329K+49.0%	-$646K-50.3%	-$430K
Retained Earnings	-$22.3M-6.8%	-$20.9M-18.5%	-$17.7M-23.3%	-$14.3M-748.1%	$2.2M	N/A

Metric	Q3'19	Q2'19	Q1'19	Q4'18	Q3'18	Q2'18	Q1'18	Q4'17
Total Assets	$7.1M-6.7%	$7.6M-13.9%	$8.8M+2196.5%	$384K-28.3%	$535K+1385.0%	$36K-45.7%	$66K-49.9%	$133K
Current Assets	$556K-17.9%	$677K-59.2%	$1.7M+1012.0%	$149K-49.6%	$296K+793.0%	$33K-47.8%	$64K-51.1%	$130K
Cash & Equivalents	$407K-14.2%	$474K-68.6%	$1.5M+2242.0%	$65K-74.2%	$250K+2418.2%	$10K-78.7%	$47K-58.5%	$112K
Inventory	$7K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.7M-14.8%	$4.3M+1.5%	$4.2M+883.6%	$429K+21.9%	$352K-73.3%	$1.3M-26.6%	$1.8M+12.0%	$1.6M
Current Liabilities	$3.7M	N/A	N/A	$429K+186.1%	$150K-88.6%	$1.3M-26.6%	$1.8M+12.0%	$1.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.4M+3.9%	$3.3M-28.1%	$4.6M+10220.7%	-$45K-124.8%	$183K+114.2%	-$1.3M+25.9%	-$1.7M-17.5%	-$1.5M
Retained Earnings	-$27.1M-14.2%	-$23.8M-6.3%	-$22.3M-7.8%	-$20.7M-1.6%	-$20.4M+2.5%	-$20.9M0.0%	-$20.9M-1.6%	-$20.6M

BETRF Cash Flow Statement

Metric	FY18	FY17	FY16	FY15	FY13	FY12
Operating Cash Flow	-$396K	N/A	-$164K-246.9%	-$47K-49.6%	-$32K	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$361K	N/A	$240K+407.7%	$47K+57.7%	$30K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'19	Q2'19	Q1'19	Q4'18	Q3'18	Q2'18	Q1'18	Q4'17
Operating Cash Flow	-$706K+28.2%	-$983K+47.5%	-$1.9M-855.5%	-$196K-103.7%	-$96K-149.6%	-$39K+40.7%	-$65K+34.8%	-$100K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$327K	$0+100.0%	-$333K	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$998K+1277.7%	-$85K-102.3%	$3.7M+13064.2%	$28K-90.9%	$307K+1265.0%	$23K+650.0%	$3K+283.8%	-$2K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BETRF Financial Ratios

Metric	FY18	FY17	FY16	FY15	FY13	FY12
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-2.6%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-1.4%	N/A	N/A	N/A	N/A	N/A
Current Ratio	N/A	0.04-0.1	0.09-0.1	0.24+0.2	0.03+0.0	0.01
Debt-to-Equity	0.92+2.0	-1.04+0.1	-1.11+0.2	-1.32-0.3	-1.03-0.0	-1.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'19	Q2'19	Q1'19	Q4'18	Q3'18	Q2'18	Q1'18	Q4'17
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-98.5%-55.6pp	-42.9%-7.5pp	-35.4%	N/A	290.1%	N/A	N/A	N/A
Return on Assets	-47.7%-29.1pp	-18.6%-0.2pp	-18.4%	N/A	99.2%+114.6pp	-15.4%+466.2pp	-481.6%	N/A
Current Ratio	0.15	N/A	N/A	0.35-1.6	1.97+1.9	0.03-0.0	0.04-0.0	0.08
Debt-to-Equity	1.06-0.2	1.30+0.4	0.92+10.4	-9.46-11.4	1.93+3.0	-1.03+0.0	-1.04+0.1	-1.09
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Genflow Biosciences GENFF

$30.7M

Marvel Biosciences Corp MBCOF

$7.4M

ZEO ScientifiX ZEOX

$13.5M

Sirona Biochem SRBCF

$1.6M

Preveceutical PRVCF

$7.7M

Frequently Asked Questions

Is Betterlife Pharma Inc profitable?

No, Betterlife Pharma Inc (BETRF) reported a net income of -$121K in fiscal year 2018.

What is Betterlife Pharma Inc's return on equity (ROE)?

Betterlife Pharma Inc (BETRF) has a return on equity of -2.6% for fiscal year 2018, measuring how efficiently the company generates profit from shareholder equity.

What is Betterlife Pharma Inc's operating cash flow?

Betterlife Pharma Inc (BETRF) generated -$396K in operating cash flow during fiscal year 2018, representing cash generated from core business activities.

What are Betterlife Pharma Inc's total assets?

Betterlife Pharma Inc (BETRF) had $8.8M in total assets as of fiscal year 2018, including both current and long-term assets.

How much does Betterlife Pharma Inc spend on research and development?

Betterlife Pharma Inc (BETRF) invested $70K in research and development during fiscal year 2018.

How many shares does Betterlife Pharma Inc have outstanding?

Betterlife Pharma Inc (BETRF) had 88M shares outstanding as of fiscal year 2018.

What is Betterlife Pharma Inc's debt-to-equity ratio?

Betterlife Pharma Inc (BETRF) had a debt-to-equity ratio of 0.92 as of fiscal year 2018, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Betterlife Pharma Inc's return on assets (ROA)?

Betterlife Pharma Inc (BETRF) had a return on assets of -1.4% for fiscal year 2018, measuring how efficiently the company uses its assets to generate profit.

What is Betterlife Pharma Inc's cash runway?

Based on fiscal year 2018 data, Betterlife Pharma Inc (BETRF) had $1.5M in cash against an annual operating cash burn of $396K. This gives an estimated cash runway of approximately 46 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Are Betterlife Pharma Inc's earnings high quality?

Betterlife Pharma Inc (BETRF) has an earnings quality ratio of 3.26x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Betterlife Pharma Inc cover its interest payments?

Betterlife Pharma Inc (BETRF) has an interest coverage ratio of -38.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.